NEW YORK, March 28, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding CR
Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align
Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and
PAREXEL International Corporation (NASDAQ: PRXL). Private wealth
members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
CR Bard Inc. Analyst Notes
On March 25, 2014, CR Bard Inc.
(CR Bard) announced that it will present at the Needham Healthcare
Conference in New York City on
April 8, 2014. As stated by the
Company, Timothy M. Ring, Chairman
and CEO, will discuss the Company in a presentation scheduled to
begin at 8:00 a.m. EDT. According to
CR Bard, a live webcast of the presentation as well as question and
answer session will be accessible to all investors through Bard's
website at http://investorrelations.crbard.com. The webcast will
also be available on the website for future on-demand replay. The
full analyst notes on CR Bard Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/03282014/BCR/report.pdf
--
Medivation, Inc. Analyst Notes
On March 18, 2014, Medivation,
Inc. (Medivation), together with Astellas Pharma Inc. (Astellas
Pharma), announced the submission of a supplemental New Drug
Application (sNDA) to the U.S. Food and Drug Administration (FDA)
seeking approval of XTANDI (enzalutamide) capsules for the
treatment of men with metastatic castration-resistant prostate
cancer (mCRPC) who have not received chemotherapy. According to the
Companies, the sNDA application is based on the results from the
Phase 3 PREVAIL trial evaluating XTANDI as compared to placebo in
more than 1,700 chemotherapy-naïve mCRPC patients and that the
marketing authorization application is expected to be submitted to
the European Medicines Agency later this year. The full analyst
notes on Medivation, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03282014/MDVN/report.pdf
--
Align Technology Inc. Analyst Notes
On March 21, 2014, Align
Technology Inc. (Align) announced that the International Trade
Commission (ITC) extended the target date for completion of its
review of the Initial Determination in the ClearCorrect
investigation. The new target date is April
3, 2014. Align stated that although the Commission did not
indicate the reason for the extension, the fact that the Commission
received significant public comment could explain the brief further
delay. The Company first filed an ITC complaint against
ClearCorrect on March 1, 2012,
asserting that ClearCorrect's aligners are made using digital data
and treatment plans imported from Pakistan that infringe Align's patents. Align
also has a patent infringement action pending against ClearCorrect
in the United States District Court for the Southern District of
Texas alleging infringement of
nine Align patents, including four additional patents not included
in the ITC litigation. The full analyst notes on Align Technology
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03282014/ALGN/report.pdf
--
Covance Inc. Analyst Notes
On March 25, 2014, Covance Inc.
(Covance) announced that it is building on its expertise in
biologics development with new investments to meet growing client
demand, including the expansion of its global bioanalytical
footprint and the addition of scientific leaders to its biologics
team. "Our new biologics solutions will enable us to work in closer
collaboration with our clients, providing them actionable insights
to help expedite their large molecule development," said
Deborah Keller, Executive Vice
President, R&D Laboratories, Covance. Ms. Keller also added,
"Doubling our large molecule capacity and enhancing a leading team
with additional dedicated scientific experts with proven success in
managing through these complexities will further strengthen our
leadership position in a growing market." The full analyst notes on
Covance Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03282014/CVD/report.pdf
--
PAREXEL International Corporation Analyst Notes
On March 19, 2014, PAREXEL
International Corporation (PAREXEL) announced the expansion of its
global Clinical Logistics Services (CLS) capabilities. As stated by
the Company, a new, state-of-the-art distribution center in
Singapore and the recent expansion
of the Company's facilities in Billerica,
Massachusetts, will help PAREXEL more effectively manage
clients' global clinical trial supply requirements. "As clinical
trials increase in size and complexity, clients are challenged to
develop and implement strategies that create consistent sourcing,
manufacturing, storage and distribution processes along the supply
chain," said Mark A. Goldberg,
President and Chief Operating Officer. "Our investments in these
important distribution centers and depots are part of the Company's
ongoing efforts to simplify the clinical trial journey for
biopharmaceutical clients by supporting their growing global supply
and logistics needs," Mr. Goldberg further added. The full analyst
notes on PAREXEL International Corporation are available to
download free of charge at:
http://www.AnalystsReview.com/03282014/PRXL/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review